Chikao Morimoto is a Professor and Chairman of the Division of Clinical Immunology, Advance Clinical Research Center, and Director of the Department of Allergy and Rheumatology, Research Hospital, Institute of Medical Science, The University of Tokyo. He was graduated from School of Medicine, Keio University, in 1973, and received the Ph.D. degree from the Graduate School of Medicine, Keio University, in 1978. He was in Dana-Farber Cancer Institute, Harvard Medical School, from 1979 to 1989; and from 1988 to 1995, he was an Associate Professor of medicine, Harvard Medical School. In 1995, he accepted a position of Professor of Medicine, Institute of Medical Science, The University of Tokyo. He was the first to define in man the functional heterogeneity amongst CD4 cells based on the differential cell surface expression of CD45, CD29, CD26, CD27, and CD70. Not only have his studies contributed to the most basic aspects of human immunobiology but more importantly have led to the application of the new and fundamental knowledge to both the clinical diagnosis and understanding of autoimmune disease. He has been listed as a Highly Cited Researcher (ISI) in the immunology field. His current research focuses on the structure and function of CD26 and beta-1 integrin in immunology and cancer. Moreover, he is a Renowned Translational Research Scientist, and anti-CD26 mAb therapy is soon in the first clinical trial for T-cell lymphoma and CD26 positive cancers.
Biography Updated on 9 May 2007